ArticleClinical and experimental medicine2025
miR-3662 targets CAB39L to promote proliferation and invasion in gastric cancer.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The evolving landscape of the Warburg effect in gastric cancer: From molecular mechanisms to targeted therapy.Clinical and translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Gastric cancer (GC) represents a highly aggressive malignancy within the gastrointestinal tract. The expression of miR-3662 exhibits specificity across different tumor types, but its precise biological role in GC pathogenesis remains poorly understood. Based on the results of bioinformatics analysis, we observed that miR-3662 was significantly overexpressed in GC. Subsequently, we investigated the biological role of miR-3662 in regulating the malignant phenotype of GC cells. Bioinformatics prediction combined with dual-luciferase assay confirmed that CAB39L is a direct target of miR-3662. Functional gain- and loss-of-function experiments were conducted to explore the impact of the miR-3662/CAB39L axis on the malignant characteristics of GC cells, as well as its influence on the activation of the AMPK signaling pathway and the expression of key glycolytic proteins. The results demonstrated that miR-3662 overexpression enhanced the proliferation, invasion, and migration of AGS cells, upregulated the expression of PFKP and LDHA, while suppressing apoptosis and reducing AMPK phosphorylation. Conversely, silencing miR-3662 exhibited opposing effects in HGC-27 cells. CAB39L expression was found to be downregulated in GC tissues. Upregulation of CAB39L inhibited GC cell proliferation, invasion, and migration, decreased the expression of PFKP and LDHA, and increased both apoptosis and AMPK activation. Furthermore, overexpression of CAB39L partially counteracted the promoting effects of high levels of miR-3662 on the malignant biological phenotype of GC cells. In conclusion, this study reveals that miR-3662 acts as a carcinogenic regulator in GC by targeting CAB39L, with the underlying mechanism potentially involving the modulation of AMPK activation to enhance cellular glycolysis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.